Glitazones linked to 22% reduced dementia risk: Study

Written By : Isra Zaman

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2022-10-15 03:30 GMT | Update On 2022-10-15 03:30 GMT

Use of an older class of type 2 diabetes drugs called glitazones, also known as thiazolidinediones or TZDs for short, is linked to a 22% reduced risk of dementia, reveals a long term study published in the open access journal BMJ Open Diabetes Research and Care.

Because type 2 diabetes and dementia share some of the same physiological patterns, researchers have started to look at whether diabetes drugs might also help stave off or treat dementia. But to date, the findings have been inconsistent.

For the study the researchers compared dementia risk in older people with type 2 diabetes and treated with either a sulfonylurea or a thiazolidinedione (TZD) with those treated with metformin alone. They drew on the electronic health records of 559,106 people diagnosed with type 2 diabetes from the national Veteran Affairs (VA) Health System, spanning the period from January 2000 to December 2019.

Only older patients (aged at least 60) and given a first prescription of metformin, or a sulfonylurea (tolbutamide, glimepiride, glipizide, or glyburide), or a TZD (rosiglitazone or pioglitazone) between January 2001 and December 2017 were included (559,106) in the study. Their health was tracked for an average of nearly 8 years.

After at least 1 year of drug treatment, use of a TZD alone was associated with a 22% lower risk of dementia from any cause, compared with the use of metformin alone. Specifically, it was associated with an 11% lower risk of Alzheimer's disease and a 57% lower risk of vascular dementia.

While the risk of dementia from any cause was 11% lower for the use of metformin and TZD combined, it was 12% higher for the use of a sulfonylurea drug alone, prompting the researchers to suggest that supplementing a sulfonylurea with either metformin or a TZD may partially offset these effects.

Further in-depth analysis indicated that those younger than 75 benefited more from a TZD than older patients, highlighting the importance of early prevention for dementia, note the researchers. And these drugs also seemed to be more protective in overweight or obese patients.

Reference:

Dr Jin J Zhou et al, Use of oral diabetes medications and the risk of incident dementia in US veterans aged ≥60 years with type 2 diabetes doi 10.1136/bmjdrc-2022-002894 Journal: BMJ Open Diabetes Research and Care

Full View

Article Source : BMJ Open Diabetes Research & Care journal

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Isra Zaman

Isra Zaman is a Life Science graduate from Daulat Ram College, Delhi University, and a postgraduate in Biotechnology from Amity University. She has a flair for writing, and her roles at Medicaldialogues include that of a Sr. content writer and a medical correspondent. Her news pieces cover recent discoveries and updates from the health and medicine sector. She can be reached at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Glitazones linked to 22% reduced dementia risk: Study

Similar News

Is Air Pollution Quietly Increasing Brain Tumour Risk? Study Sheds Light

Even Low Lead Exposure May Accelerate Memory Loss in Children: Study Finds

Improved Survival Rates for People with Dementia: Global Study Finds

Is Your Brain Aging Too Fast? New Study Can Tell from One Brain Scan

Even in Your 70s, Your Brain May Be Making New Memory Cells: Study Suggests

New AI Tool Accurately Detects Nine Types of Dementia Using Single Brain Scan: Study Shows

Can Electric Fields Help Heal Spinal Cord Injuries? Study Provides Insights

Simple Blood Test Identifies Alzheimer's Patients at Risk of Faster Decline: Study Shows